On Monday, Intellia Therapeutics Inc (NASDAQ: NTLA) was 10.12% up from the session before settling in for the closing price of $10.38. A 52-week range for NTLA has been $5.90 – $28.25.
A company in the Healthcare sector has dropped its sales by -20.04% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 23.97%. With a float of $109.90 million, this company’s outstanding shares have now reached $115.79 million.
Intellia Therapeutics Inc (NTLA) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Intellia Therapeutics Inc stocks. The insider ownership of Intellia Therapeutics Inc is 5.12%, while institutional ownership is 86.30%. The most recent insider transaction that took place on Jan 05 ’26, was worth 314,485. In this transaction President and CEO of this company sold 34,146 shares at a rate of $9.21, taking the stock ownership to the 1,013,339 shares. Before that another transaction happened on Jan 05 ’26, when Company’s EVP, Chief Scientific Officer sold 8,508 for $9.21, making the entire transaction worth $78,359. This insider now owns 98,533 shares in total.
Intellia Therapeutics Inc (NTLA) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -1.27 earnings per share (EPS) during the time that was better than consensus figure (set at -1.32) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.99 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.85% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
You can see what Intellia Therapeutics Inc (NTLA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 23.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.27, a number that is poised to hit -0.96 in the next quarter and is forecasted to reach -3.62 in one year’s time.
